Neoadjuvant gemcitabine, cisplatin, plus nivolumab in patients with muscle-invasive bladder cancer with selective bladder sparing

Status: Closed to Accrual

Learn more:

• https://clinicaltrials.gov/study/NCT03558087
• News release

Manuscripts/Articles: 

• M Galsky, S Daneshmand, S Izadmehr, E Gonzalez-Kozlova, K Chan, S Lewis, B El Achkar, T Dorff, J Paul Cetnar, B Neil, A D’Souza, R Mamtani, C Kyriakopoulos, T Jun, M Gogerly-Moragoda, R Brody, H Xie, K Nie, G Kelly, A Horwitz, Y Kinoshita, E Ellis, Y Nose, G Ioannou, R Cabal, G Kenneth Haines, L Wang, K Mouw, R Samstein, R Mehrazin, N Bhardwaj, M Yu, Q Zhao, S Kim-Schulze, R Sebra, J Zhu, S Gnjatic, J Sfakianos, S K. Pal. Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial HCRN-GU16-257. DOI: 10.1038/s41591-023-02568-1 Nature Communications. 2023 October 2. See Abstract. 

Abstracts/Posters/Presentations:

• MD Galsky, S Daneshmand, KG Chan, TB Dorff, JP Cetnar, B O’Neil, A D’souza, R Mamtani, C Kyriakopoulos, P Garcia, S Izadmehr, M Yu, Q Zhao, R Mehrazin, SC Lewis, J Sfakianos, SK Pal. Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle- invasive bladder cancer (MIBC): HCRN GU16-257. Presented as an oral abstract at the ASCO 2021 Annual Meeting. J Clin Oncol 39, 2021 (suppl 15; abstr 4503) See abstract. See related coverage at cancernetwork.com.

Study Contact: studies@hoosiercancer.org; (317) 921-2050.